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Synergistic Activation of Human Involucrin Gene
Expression by Fra-1 and p300—Evidence for the
Presence of a Multiprotein Complex
James F. Crish1 and Richard L. Eckert1,2,3,4,5
Involucrin is expressed in the differentiated suprabasal epidermal layers, and an AP1 transcription factor-
binding site present in the involucrin promoter distal regulatory region is required for this regulation. This site
binds Fra-1, but cofactor interaction at this site has not been adequately characterized. We show that Fra-1 and
p300 histone acetyltransferase are present at the AP1 site, as detected by chromatin immunoprecipitation. This
interaction is functional, as treating p300 expressing keratinocytes with calcium or 12-O-tetradeconylphorbol-
13-acetate, results in a synergistic increase in hINV expression, and this enhanced activation can be reproduced
by coexpression of Fra-1 and p300. p300 also co-precipitates with Fra-1, but protein fractionation studies suggest
that this interaction requires an additional protein. Fra-1 also interacts with other proteins that interact at the
AP1-5 site, including JunD, JunB, Sp1, and P/CAF. Contrary to results in some other systems, Fra-1 functions as a
positive transcriptional regulator in human keratinocytes. These studies suggest that a large multiprotein
complex, which includes Fra-1, p300, P/CAF, junD, junB, and Sp1 acts at the AP1-5 site to produce a synergistic
increase in hINV gene expression.
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INTRODUCTION
Epidermal keratinocytes undergo a programmed transition, in
which undifferentiated proliferating cells are converted to non-
proliferating, terminally differentiated cells (Eckert et al., 1997b).
This differentiation process is tightly controlled and involves
specific temporal and spatial changes in gene expression (Eckert
and Welter, 1996; Eckert et al., 1997a, b). The ultimate product
of keratinocyte differentiation is the corneocyte, which consists
of a covalently crosslinked sheath of protein, called the
cornified envelope, surrounding a network of stabilized keratin
fibrils. Millions of corneocytes are assembled to construct the
epidermal surface (Reichert et al., 1993; Steven and Steinert,
1994; Steinert, 1995; Steinert and Marekov, 1997).
Involucrin is a key cornified envelope precursor protein
and is covalently incorporated to form the cornified envelope
scaffolding via the action of type I transglutaminase (Simon
and Green, 1985, 1988; Etoh et al., 1986; Yaffe et al., 1992).
Involucrin expression is regulated during differentiation—the
involucrin gene is not expressed in the basal epidermal layer,
but expression is observed in cells occupying the upper-
spinous and granular layers (Rice and Green, 1977, 1979).
Involucrin is also expressed in other stratifying epithelia, and
in each tissue, expression is confined to the suprabasal layers
(Banks-Schlegel and Green, 1981; Crish et al., 1993). Thus,
involucrin is an important model for the study of tissue-
specific and differentiation-dependent gene expression. Pre-
vious studies show that a 6-kb segment of the hINV gene,
including the hINV upstream regulatory region, the transcrip-
tion start site, the intron, and the coding sequence, guides
appropriate tissue-specific and differentiation-appropriate
expression in transgenic mice (Crish et al., 1993). Targeted
expression is also observed when the upstream regulatory
region, nucleotides 2,473/1, is linked to the human
papillomavirus oncoproteins (Crish et al., 2000), suggesting
that this region is sufficient to direct appropriate expression.
In vitro studies show that the promoter is expressed in cells
derived from stratifying epithelia (Welter et al., 1995; Banks
et al., 1999), is regulated by agents that modulate differentia-
tion (Efimova et al., 1998, 2002; Efimova and Eckert, 2000),
and is not active in fibroblasts (Welter et al., 1995). Deletion
mapping and point mutation studies identify two regions of
the upstream regulatory region, the proximal regulatory
region (PRR) and the distal regulatory region (DRR), that are
required for optimal expression in cultured cells (Welter
et al., 1995; Banks et al., 1999). The DRR contains AP1 and
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Sp1 sites, separated by one nucleotide, that are required for
optimal promoter activity (Welter et al., 1995). The DRR Sp1
site acts synergistically to activate transcription, in conjunc-
tion with the AP1-5 site (Banks et al., 1999). Gel mobility
supershift studies indicate that junB, junD, and Fra-1 interact
with the DRR AP1-5 site, and that Sp1 and Sp3 factors
interact with the DRR Sp1 site (Welter et al., 1995; Banks
et al., 1998; Balasubramanian et al., 2002). We have
proposed that a complex is formed on the DRR that includes
AP1 and Sp1 factors and other, presently unknown,
coactivators (Eckert et al., 2004).
CREB binding protein and p300 acetyltransferases
CREB binding protein (CBP) and p300 are histone acetyl-
transferases (HATs) that are ubiquitously expressed and
participate in a host of gene regulatory events (Partanen
et al., 1999). An amino-acid sequence comparison of these
multidomain proteins reveals numerous conserved regions,
including three cysteine–histidine-rich regions (CH1, CH2,
CH3), the CREB transcription factor-binding site (KIX
domain), the bromodomain, the HAT domain, and the steroid
receptor coactivator-1 interaction domain (Arany et al.,
1994). CBP and p300 interact with basal transcription factors,
including TATA-binding protein (Yuan et al., 1996) and TFIIB
(Kwok et al., 1994; Yuan et al., 1996), and can complex with
RNA polymerase II (Nakajima et al., 1997a, b; Cho et al.,
1998; Neish et al., 1998). These interactions occur through
an N- and C-terminal activation domain (AD). CBP and p300
also bind to other proteins via the CH1, CH3, KIX, and steroid
receptor coactivator-1 interaction domain domains (Chan
and La Thangue, 2001; Vo and Goodman, 2001). CBP and
p300 can act as physical bridges by simultaneous interaction
with basal transcription factors and upstream transcriptional
regulators. In addition, these protein–protein interactions are
influenced by the post-translational modifications, including
phosphorylation (Janknecht and Nordheim, 1996; it-Si-Ali
et al., 1998), sumoylation (Girdwood et al., 2003), and
methylation (Chevillard-Briet et al., 2002; Girdwood et al.,
2003).
These studies are designed to gain new insight regarding
the composition of the gene regulatory complexes that
regulate involucrin gene expression. Our studies show that
p300 acts as a potent coactivator of hINV gene expression
that, when overexpressed in differentiation agent-treated
cells, results in a synergistic increase in hINV gene
expression. We have previously shown that Fra-1 is a key
regulator that binds at the hINV promoter AP1 factor DNA-
binding sites (Welter et al., 1995). Our present studies
indicate that Fra-1/p300 coexpression results in synergistic
activation of hINV promoter activity. Moreover, chromatin
immunoprecipitation (ChIP) analysis reveals that both pro-
teins are bound to the promoter in the vicinity of the AP1-5
site. Immunoprecipitation analysis reveals that Fra-1 interacts
with p300, and protein fractionation studies suggest that this
interaction requires an additional unknown protein. In
addition, JunD, JunB, p300, P/CAF, and Sp1 co-precipitate
with Fra-1, suggesting that a large multiprotein complex
regulates expression.
RESULTS
Calcium and 12-O-tetradeconylphorbol-13-acetate (TPA) are
known regulators of keratinocyte differentiation. Treatment
with either agent results in an increase in hINV gene
expression and promoter activity (Welter et al., 1995; Banks
et al., 1998; Deucher et al., 2002; Efimova et al., 2003). p300
and CBP are ubiquitously expressed acetyltransferases that
participate in gene regulatory events in a range of cell types
(Giordano and Avantaggiati, 1999; Chan and La Thangue,
2001; Iyer et al., 2004; Kalkhoven, 2004) by acetylating the N
termini of several core histones (Giordano and Avantaggiati,
1999; Chan and La Thangue, 2001; Iyer et al., 2004). To
assess the role of acetyltransferases in regulating involucrin
gene expression, we examined the ability of coexpressed
p300 to increase calcium- and TPA-dependent involucrin
gene expression (Welter et al., 1995; Efimova et al., 1998;
Agarwal et al., 1999). Keratinocytes were transfected with the
involucrin promoter luciferase reporter plasmids, as shown in
Figure 1a. pINV-2473 encodes the full-length involucrin
promoter, whereas pINV-41 encodes 41 nucleotides that
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Figure 1. Calcium treatment of p300 expressing keratinocytes produces a
synergistic increase in hINV promoter activity. (a) Structure of hINV
luciferase reporter constructs. pINV-2473 includes the full-length hINV
promoter; pINV-41 is the hINV basal promoter (TATA box only). The
locations of the proximal and distal regulatory regions are indicated (PRR,
DRR), as are the positions of the AP1-1 and AP1-5 sites, the C/EBP site, and
the Sp1 site. The black box represents the luciferase gene and the arrow
indicates the site of transcription initiation and the direction of transcription.
(b and c) Calcium treatment of p300 expressing cells results in synergistic
activation of involucrin gene transcription. Keratinocytes (50% confluent)
were transfected with 1 mg of pINV-2473 or pINV-41 in the presence or
absence of 0.5 mg of p300 expression plasmid. After 24 hours, the cultures
were shifted to cell culture medium supplemented or not supplemented with
0.3mM calcium, for an additional 24 hours. For TPA treatment, the cells were
transfected as indicated above and then treated for 24 hours in the presence or
absence of 50 ng TPA/ml. Cell extracts were then prepared for assay of
luciferase activity. The values presented in this figure represent the averages of
four separate experiments. As assessed by the Student’s t-test, for the pINV-
2473 construct, the difference between the control and all other groups is
significant at the 95% confidence level. The difference between the 0.3mM
calcium/TPAþ p300 groups and all other groups is significant at the 95%
confidence interval.
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constitute the hINV minimal promoter (Welter et al., 1995).
Keratinocytes were transfected with pINV-41 and pINV-2473
in the presence or absence of p300 expression vector and
then treated with calcium or TPA. After 24 hours, the cells
were harvested and assayed for luciferase activity. As shown
in Figure 1b, pINV-41 does not respond to any of the
treatments. In contrast, the activity of pINV-2473 is markedly
increased by p300 or by addition of 0.3mM calcium.
Moreover, a synergistic activation is observed when cells
are co-treated with p300 and calcium. As shown in Figure 1c,
a similar pattern of synergistic activation is observed for cells
treated with TPAþ p300.
To assess the specificity of this regulation, TPA- and p300-
dependent pINV-2473 activity was measured in the presence
and absence of expression of the dominant-negative p300
mutant, d33, which lacks a segment of the CH3 domain
(Eckner et al., 1994; Lill et al., 1997). The reduced pINV-
2473 promoter activity, observed in the presence of d33,
suggests that acetyltransferase activity is absolutely required
for appropriate promoter activation in response to treatment
with calcium or TPA (Figure 2a). As shown in Figure 2b,
immunoblot with either anti-HA or anti-p300 confirms that
HA-p300 and HA-d33 are expressed in the transfected
keratinocytes. In addition, the anti-p300 immunoblot con-
firms the presence of endogenous p300.
p300-dependent promoter activation via the hINV promoter
DRR
Our previous studies indicate that AP1 transcription factors
interact with the hINV promoter DRR AP1-5 site to increase
involucrin promoter activity (Welter et al., 1995; Crish et al.,
1998, 2002, 2006), and that treatment with TPA or calcium
increases AP1 factor interaction at this site (Welter et al.,
1995; Deucher et al., 2002). These observations suggest that
the synergistic increase in promoter activity observed in TPA-
or calcium-treated p300 expressing cells may be due to p300
factor synergy with AP1 factors.
To test this possibility, we assessed whether Fra-1, which
binds to the AP1-5 site (Welter et al., 1995), can act with
p300 to increase activity. We focused on the DRR region
using a series of involucrin promoter luciferase reporter
plasmids, which encode various segments of the DRR (Figure
3a). As shown in Figure 3b, activity of most of the DRR
constructs is modestly increased or not regulated by Fra-1 or
p300. In contrast, a marked synergistic increase is observed
when both p300 and Fra-1 are present. It is noteworthy that
this increase is specific for constructs in which the DRR is
present, and is not observed for the minimal promoter
construct—pINV-41. As noted above, the DRR encodes an
AP1 site (AP1-5) that is essential for expression of the hINV
transgene in mice (Crish et al., 1993, 1998, 2002). To assess
the role of this site in mediating the response to p300 and Fra-
1, we tested the activity of DRR(2,473/1,953)-AP1-5mm,
in which the AP1-5 site is mutated (Welter et al., 1995). As
shown in Figure 3c, mutation of this site results in a complete
loss of the ability of p300, Fra-1, and p300þ Fra-1 to regulate
activity. It is striking that mutation of the AP1-5 results in an
inactivation of the p300-dependent increase in expression.
This provides strong evidence that the p300-dependent
synergy involves factors that bind at the AP1-5 site.
Evidence for interaction of p300 and Fra-1
Our previous studies demonstrate that Fra-1 binds to the
hINV promoter DRR AP1-5 site, as determined by gel
mobility and gel mobility supershift assay (Welter et al.,
1995). To demonstrate that Fra-1 and p300 localize at the
DRR region in vivo, we performed ChIP. Cells were
incubated with formaldehyde to crosslink proteins to DNA,
and the DNA was sheared and protein bound DNA was
precipitated with anti-IgG, anti-p300, or anti-Fra-1. As shown
in Figure 4, incubation with anti-p300 or anti-Fra-1 pre-
cipitates protein-associated DNA that is detected by PCR. In
contrast, the anti-IgG precipitate does not produce a PCR
product. This suggests that both p300 and Fra-1 are resident
in the vicinity of the DRR AP1-5 element.
To monitor direct interaction between p300 and Fra-1, we
performed co-precipitation experiments. However, the avail-
able antibodies are not adequate to detect interaction given
the low level of Fra-1 and p300 expression in keratinocytes.
As an alternate method, we utilized an immortal epithelial
cell line—HeLa-Z. We generated a HeLa-Z cell line that
overexpresses FLAG-tagged human Fra-1. This cell line was
generated by infection with pLNCX2-FLAG-hFra-1, a G418-
selectable virus that was engineered to produce FLAG-hFra-1.
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Figure 2. TPA-dependent hINV promoter activity requires p300. (a)
Keratinocytes (50% confluent) were transfected with 1 mg of pINV-2473, in
the presence or absence of 0.5mg of HA-p300 or HA-d33 expression
plasmids. The final DNA concentration was adjusted to a final concentration
of 2mg with empty plasmid. At 24 hours post-transfection, the cultures were
treated for 24 hours with or without 50 ng TPA/ml. Cell extracts were then
prepared for assay of luciferase activity. The results are the average values
derived from three separate experiments. The difference between TPA treated
and p300 groups and all other groups is significant at the 95% confidence
interval. (b) Keratinocytes were transfected with pINV-2473, HA-p300, and
HA-d33 plasmids as outlined above. At 24 hours post-transfection the cells
were harvested and total cell extracts were assayed for the presence of HA-
p300 or HA-d33 by immunoblot using antibodies specific for p300 or HA
epitope, followed by an appropriate secondary HRP-conjugated antibody and
visualization of antibody binding using chemiluminescence reagents.
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A control HeLa-Z cell line was produce by infection with
empty pLNCX2 followed by selection with G418. As shown
in Figure 5a, the pLNCX2-hFLAG-Fra-1 cells produce
substantially elevated levels of hFra-1, which can be detected
using anti-Fra-1 or anti-FLAG. To determine whether FLAG-
Fra-1 can interact with p300, we prepared extract from
pLNCX2-FLAG-hFra-1 and pLNCX2 cells for immunopreci-
pitation with anti-FLAG. The top panel in Figure 5b shows an
anti-FLAG immunoblot of anti-FLAG precipitated FLAG-hFra-
1. This figure confirms that FLAG-hFra-1 is successfully
precipitated by the antibody. We performed parallel im-
munoblots of the precipitated material using p300- and P/
CAF-specific antibodies. The middle panel in Figure 5b
shows a strong anti-p300-immunoreactive band that is
specifically precipitated in FLAG-hFra-1-expressing cells.
The lower panel shows a specific FLAG-hFra-1-dependent
precipitation of P/CAF. These findings suggest that FLAG-
hFra-1 and endogenous p300 and P/CAF are part of a
multiprotein complex.
We next assessed the ability of Fra-1 to interact with other
transcription factors that are thought to be involved in
regulation via the DRR. As shown in Figure 5c, immunopre-
cipitation of FLAG-Fra-1 results in co-precipitation of JunD,
JunB, and Sp1. These findings are significant, since JunD and
JunB have a role in regulating involucrin gene expression
(Welter et al., 1995). Moreover, there is an Sp1 site located
immediately adjacent and downstream of the AP1-5 site
within the DRR, that has been shown to be functionally
important (Banks et al., 1998, 1999; Crish et al., 1998). As
expected, Fra-1 not only interacts with AP1 factors that
specifically bind to the hINV promoter AP1 site, but also with
other AP1 factors. For example, as shown in Figure 5c, it also
precipitates c-jun, which does not interact at the AP1-5 site
(Welter et al., 1995).
Mechanism of Fra-1/p300 interaction
The above studies, using total nuclear extracts, indicate the
co-immunoprecipitation of Fra-1 and p300. However, it is
not clear whether this involves a direct Fra-1/p300 interac-
tion. To assess this, we loaded nuclear extract prepared from
HeLa-Z FLAG-hFra-1 cells, on a P11 anion-exchange
column, eluted the sample using a KCl step gradient, and
tested the fractions for Fra-1/p300 interaction. We monitored
elution of three key proteins—FLAG-hFra-1, JunB, and p300.
As shown in Figure 6, FLAG-hFra-1 and junB elute in the
0.4–0.5 M KCl fractions. p300 is also present in these
fractions, but also elutes at other KCl concentrations,
probably reflecting its ability to interact with a wide range
of proteins.
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Figure 4. In vivo interaction of p300 and Fra-1 with the hINV promoter
DRR. Normal human keratinocytes were treated with formaldehyde to
crosslink intranuclear DNA–protein complexes. The nuclei were then
prepared and lysed, and Fra-1 and p300 DNA complexes were
immunoprecipitated using 5mg rabbit anti-Fra-1 and 5 mg mouse monoclonal
anti-p300 antibodies, respectively. Nonspecific precipitation was monitored
by precipitation using normal mouse IgG (Santa Cruz, sc-2025). The DNA
was released from the precipitated complex using 1% SDS/0.1M NaHCO3
and the released product was amplified by PCR and the amplified product
was detected by ethidium staining of an agarose gel. The arrows indicate
migration of the product and the primers. M¼markers (nucleotides) and
T¼ PCR product observed following amplification of 1% of material used for
immunoprecipitation.
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Figure 3. p300 and Fra-1 act synergistically to increase hINV promoter
activity. (a) Structure of hINV luciferase reporter constructs. pINV-2473
includes the full-length hINV promoter; pINV-41 is the hINV basal promoter
(TATA box only). The conventions are exactly as outlined in Figure 1. In the
DRR constructs, segments of the DRR region are fused adjacent the hINV
basal promoter. The DRR(2,473/1,953) AP1-5mm has a mutation in the
AP1-5 site that results in its inactivation (Welter et al., 1995). (b and c)
Keratinocytes (50% confluent) were transfected with 1 mg of the indicated
DRR hINV promoter reporter plasmid in the presence of 0.5mg of HA-p300 or
FLAG-hFra-1. At 24 hours post-transfection, the cells were harvested and
extracts prepared for assay of luciferase activity. The values are the mean of
two separate experiments.
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To determine whether FLAG-hFra-1 and p300 interact
following P11 chromatography, the 0.4 M KCl fractions were
pooled, FLAG-hFra-1 was precipitated with anti-FLAG, and
precipitated proteins were detected by immunoblot. As
shown in Figure 7a, FLAG-hFra-1 is precipitated from extracts
derived from FLAG-hFra-1 expressing cells, but not from
extracts prepared from HeLa-Z cells (top panel), and the
precipitated protein co-migrates with the FLAG-hFra-1
present in total nuclear extract (NE). We next determined
whether junB co-precipitates with FLAG-hFra-1. As expected,
JunB, which can heterodimerize with Fra-1, co-precipitates
with FLAG-hFra-1 (middle panel). However, under these
conditions, p300 does not co-precipitate with FLAG-hFra-1
(bottom panel). This indicates that neither Fra-1 nor junB is
the direct binding partner of p300.
These findings suggest that the P11 chromatography step
has removed a protein partner that is necessary for Fra-1/p300
interaction. However, it is possible that the presence of 0.4 M
KCl causes p300 to dissociate. To assess the latter possibility,
we adjusted the salt concentration, of total nuclear extracts,
to 0.4, 0.5, 0.85, and 1.2 M KCl. We then precipitated FLAG-
hFra-1 and monitored for co-precipitation of JunB, JunD, and
p300. As shown in Figure 7b, all three proteins co-
precipitated at all salt concentrations, suggesting that the
absence of p300 co-precipitation observed in the Figure 7a is
not due to salt-dependent release of p300.
Fra-1 functions as a transcriptional activator
To further assess the ability of Fra-1 to drive transcription we
used a one-hybrid assay system. Keratinocytes were trans-
fected with 0.1 mg of pFR-Luc, which encodes the Gal4 DNA
response element linked upstream of luciferase, and 0.1 mg of
expression plasmids encoding the Gal4 DNA binding domain
(Gal4BD) fused to selected regions of Fra-1. As shown in
Figure 8a, minimal promoter activity is observed in cells
transfected with empty vector or with Gal4BD. In contrast,
fusion of the GAL4BD to full-length Fra-1 results in a
substantial increase in reporter activity. This activity is
progressively reduced as the Fra-1 AD is truncated. Activity
of Fra-1-D232–271 and Fra-1-D189–271 is reduced by 60 and
80%, respectively. These results suggest that the Fra-1 AD is
required for activity. Colburn and co-workers have reported
that the key threonine phosphorylation site in the Fra-1 AD is
required for optimal transcriptional activity. To assess the role
of this site, we converted T227 to glutamic acid or alanine. As
shown in Figure 8b, the Fra-1 AD (residues 131–271, Fra-1-
AD) is sufficient to drive transcription. However, mutation of
T227 to Glu or Ala reduces activity.
DISCUSSION
Involucrin gene expression—a role for AP1 and Sp1
transcription factors
Keratinocyte differentiating agents activate an nPKCd, Ras,
MEKK1, MEK3, p38d/ERK1/2 signaling cascade to increase
AP1 factor expression (Efimova et al., 1998, 2002, 2003;
Efimova and Eckert, 2000). This leads to enhanced AP1 factor
interaction at DNA-binding sites within the hINV promoter
and ultimately leads to increased hINV gene expression
(Eckert et al., 2004). The AP1-5 site, located in the DRR, is
particularly important for this regulation (Welter et al., 1995).
The absence of this site results in a marked reduction in
promoter activity in cultured keratinocytes (Welter et al.,
1995). Moreover, mutation of this site results in a complete
loss of involucrin expression in murine transgenic models of
hINV gene expression (Crish et al., 1998, 2002, 2006). These
findings indicate that AP1 factors are essential for normal
hINV gene expression. The AP1 transcriptional regulators
comprise a family of proteins that form homo- and hetero-
dimers to regulate transcription (Karin et al., 1997; Shaulian
and Karin, 2002). Members of this family are known to be
expressed in the epidermis (Welter and Eckert, 1995; Angel
et al., 2001) and to have an important role in regulating
epidermal keratinocyte gene expression, differentiation, and
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Figure 5. Evidence suggesting that p300 and Fra-1 interact. (a) Nuclear
extracts were prepared from HeLa-Z (pLNCX2) and HeLa-Z (pLNCX2-FLAG-
Fra-1) cell lines. Equal protein equivalents were separated by electrophoresis
and immunoblotted with anti-Fra-1 or anti-FLAG. (b) FLAG-Fra-1 was
precipitated from nuclear extract isolated from HeLa-Z (pLNCX2) and HeLa-Z
(pLNCX2-FLAG-Fra-1) cell lines using 5mg of mouse monoclonal anti-FLAG
M2. The precipitated protein was separated by electrophoresis and
immunoblotted with anti-FLAG (top panel), anti-p300 (middle panel), and
anti-P/CAF (bottom panel). Each group was incubated with the appropriate
HRP-conjugated secondary antibody and the signal was visualized using
chemiluminescence detection reagents. The asterisks indicate nonspecific
bands. (c) FLAG-hFra-1 precipitation of other regulatory proteins. Proteins
were immunoprecipitated using 5 mg of mouse monoclonal anti-FLAG M2 as
above and co-precipitated proteins were identified using antibodies specific
for the indicated proteins.
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transformation (Smeyne et al., 1992; Kachinskas et al., 1994;
Saez et al., 1995; Huang et al., 1996, 1997; Rutberg et al.,
1996,1997; Rossi et al., 1998; Cooper et al., 2003). Although
all of the AP1 family members are expressed in epidermal
keratinocytes, only Fra-1, JunB and JunD bind to AP1-5 DNA
binding site (Welter et al., 1995; Banks et al., 1998;
Balasubramanian et al., 2002, 2005). In addition, a canonical
Sp1 transcription factor-binding site is located immediately
downstream and adjacent to the AP1-5 site (Banks et al.,
1998). Mutation of this site results in reduced hINV
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Figure 6. P11 column fractionation of nuclear extracts. Nuclear extract (NE, 2.5mg) was prepared from HeLa-Z (pLNCX2-FLAG-hFra1) cells and
chromatographed on a 3ml P11 phosphocellulose column (Whatman) at a flow rate of 1 column volume per hour. The column, which was prepared in
equilibration buffer containing 0.2M KCl (see Materials and Methods), was sequentially eluted with 1ml equilibration buffer containing 0.3, 0.4, 0.5, 0.85, and
1.2M KCl and 0.25ml fractions were collected. Each fraction was then dialyzed against the equilibration buffer and an equivalent quantity of protein (15mg) was
separated by electrophoresis on a 10% (FLAG-hFra-1) or 5% (p300) polyacrylamide gel before immunoblotting. FLAG-hFra-1 was detected using peroxidase-
conjugated anti-FLAG M2 mouse monoclonal antibody (Sigma F1804, 1:500), and JunB and p300 were detected using a 1:500 dilution of rabbit anti-JunB (Santa
Cruz, sc-46X) and 2mg/ml mouse monoclonal anti-p300CT (Upstate, 05-257), respectively.
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expression in transgenic mouse models (Crish et al., 2006).
Although Fra-1, JunB, and JunD, and Sp1 are known to bind
to the DRR AP1-5/Sp1 element, very little is known about the
role of coactivators in driving expression.
Involucrin gene expression—a role of HATs
HATs function to acetylate histones and other proteins, and
also serve as bridge proteins during transcription complex
assembly (Giordano and Avantaggiati, 1999). The acetylation
catalyzed by these proteins is thought to modulate complex
formation to from an open chromatin structure that is
accessible for transcription (Giordano and Avantaggiati,
1999; Chan and La Thangue, 2001). As such, the p300 and
P/CAF HATs have been shown to interact with a variety of
transcriptional regulators (Giordano and Avantaggiati, 1999);
however, the function of these proteins has not been
extensively studied in epidermis or in epidermal keratino-
cytes. In this study, we examine the role of these proteins in
regulating hINV gene expression. Our studies show that
treatment of keratinocytes with differentiating agents (TPA or
calcium) in the presence of overexpressed p300 results in a
synergistic increase in hINV promoter activity. We further
show that this activation can be completely blocked by
expression of dominant-negative p300 or by mutation of the
AP1-5 binding site. We anticipate that hINV gene expression
is regulated by a complex and redundant set of mechanisms.
Thus, it is very interesting that mutation of the AP1-5 site
(elimination of transcription factor DNA interaction) or
expression of dominant-negative p300 (inhibition of HAT
function) is able to eliminate promoter activity. This is
consistent with previous reports indicating that expression of
a mutant form of P/CAF can inhibit the calcium-dependent
increase in involucrin expression in HaCaT cells (Kawabata
et al., 2002), and that expression of p300 or P/CAF, in
immortalized keratinocyte cell lines that express reduced
levels of involucrin, results in enhanced expression (Tran and
Crowe, 2004). These findings strongly suggest that both AP1
factor and HAT function are absolutely required for promoter
activation. Moreover, coexpression of Fra-1 with p300 results
in a synergistic increase in promoter activity, indicating that
these factors function together to drive transcription.
We further demonstrate, using ChIP, that Fra-1 and p300
interact at the AP1-5/Sp1 element in the DRR region—thus
placing both proteins in physical proximity over this element.
This finding is consistent with a previous report indicating that
p300 and P/CAF interact with the hINV promoter AP1-1 and
AP1-5 sites (Tran and Crowe, 2004). To study the composition
and structure of this multiprotein complex, we expressed
FLAG-hFra-1 in HeLa-Z cells, and then precipitated with anti-
FLAG. This study revealed that endogenous p300 can co-
precipitate with Fra-1, and that a second HAT protein, P/CAF,
also interacts with Fra-1. These findings suggest that Fra-1 is
part of a complex that may serve to increase hINV promoter
activity by bringing p300 and P/CAF into proximity with the
DRR element. We also assessed whether Fra-1 and p300
interact in a direct manner, since the direct interaction of
p300 with fos family proteins has been reported (Bannister
and Kouzarides, 1995; Bannister et al., 1995). P11 chromato-
graphy of total nuclear extract results in the loss of ability of
p300 to co-precipitate with FLAG-hFra-1. These findings
suggest that a Fra-1/JunB heterodimer is present, and that the
Fra-1 protein present in this complex interacts with p300 via a
bridging protein. The identity of this bridge protein is presently
not known. It is possible that this interaction could occur via
p300 or P/CAF interaction with the JunB protein present in the
complex with hFra-1, as these HAT proteins have been shown
to interact with jun family members (Bannister et al., 1995).
However, this appears unlikely since FLAG-hFra-1 and JunB
co-precipitate in the absence of p300 co-precipitation in P11
fractionated proteins.
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Figure 8. Fra-1 as a transcriptional activator. Normal human keratinocytes
were transfected with 0.1 mg of pFR-Luc in the presence of 0.1 mg of the
indicated Gal4-BD-FLAG-Fra-1 protein expression constructs. At 24 hours
after transfection, the cells were harvested and assayed for luciferase activity.
(a) Regulation of pFR-Luc promoter activity by full-length Fra-1 and truncation
mutants. Keratinocytes were transfected with 0.1 mg of pFR-Luc in the present
of 0.1mg of the indicated plasmids. After 24 hours, the cells were harvested
and extracts were assayed for luciferase activity. (b) Regulation of pFR-Luc
promoter activity by the Fra-1 AD and Fra-1 AD truncation mutants.
Keratinocytes were transfected and harvested for assay of luciferase activity as
outlined above. The data is expressed as the mean7SEM, n¼ 4. Immunoblot
analysis reveals that all of the proteins (GAL4BD-FLAG-Fra-1, and so on) were
expressed at comparable levels (not shown). The results are a representative
experiment from two repeats. The values are expressed as sample
means7SD.
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Parallel studies indicate that JunB, JunD, and Sp1 also co-
precipitate with FLAG-hFra-1, a finding that is consistent with
a previous report indicating that p300 interacts with Fra-1,
FosB, and junB in immortal and transformed SCC-12
keratinocytes (Tran and Crowe, 2004). Taken together, these
studies suggest that a large complex, which includes junB,
junD, Sp1, Fra-1, p300, and P/CAF, is likely to exist in the
vicinity of the DRR AP1-5/Sp1 element. It is possible that one
or more of these proteins provides the physical contact that
permits Fra-1/p300 interaction—however, it does not appear
to be junB. Candidates for the protein that may mediate
physical interaction with p300 include Sp1, which has been
reported to functionally interact with p300 (Hung et al.,
2006). At least one example of a function relationship
between Sp1 and p300 exists in keratinocytes—the loricrin
gene is increased when keratinocytes are cotransfected with
Sp1 or c-jun in the presence of p300 (Jang and Steinert,
2002), suggesting that p300 serves as a coactivator of loricrin
expression (Jang and Steinert, 2002). A role for p300 is also
indicated for control of keratin 14 expression, where it drives
increased expression via interaction with the POU domain
protein, Skin-1a (Sugihara et al., 2001).
Fra-1 as a transcriptional activator
Fra-1 has previously been thought to lack the ability to drive
transcription due to the absence of a functional transactiva-
tion domain (Wisdom et al., 1992; Wisdom and Verma,
1993; Bergers et al., 1995); however, Fra-1 can also act to
enhance cell responses (Mechta et al., 1997; Vallone et al.,
1997; Kustikova et al., 1998; Young et al., 2002), suggesting
that it is likely to have transcriptional activity. Our studies
demonstrate that Fra-1 acts as a positive activator of hINV
promoter activity in keratinocytes. Moreover, parallel studies
indicate that the isolated Fra-1 AD can positively regulate
transcription from the GAL4 promoter. These studies indicate
that the hFra-1 AD is sufficient to drive gene expression in
human keratinocytes. Colburn and co-workers demonstrated
that mutation of threonine 227 to alanine in Fra-1 results in a
loss of Fra-1 activity (Young et al., 2002). We were able to
replicate this result in the present studies; however, we also
observed a drop in activity for a threonine 227 to glutamic
acid mutant. Thus, the charge distribution at this residue must
be important for activity.
Regulation of involucrin gene expression—a role for p300 and
P/CAF
Previous studies demonstrate that the hINV promoter AP1-5
and Sp1 sites, located in the distal regulatory region of the
promoter, are essential for expression of the hINV transgene
in murine epidermis (Crish et al., 1993, 1998, 2002, 2006).
Cell culture-based studies, using normal human keratino-
cytes, indicate that a protein kinase C, Ras, MEKK3, MEK3
signaling cascade, acting via regulation of a p38d-ERK1/2
complex, acts to increase the intracellular levels of AP1 and
Sp1 transcription factor, which interact at the AP1-5 site and
an adjacent Sp1 site. This complex includes Fra-1, junB,
junD, and Sp1 (Welter et al., 1995; Banks et al., 1998, 1999).
These studies strongly suggest that p300 and P/CAF partici-
pate as part of a multiprotein complex to regulate expression
via interaction at the DRR AP1-5/Sp1 element; however, we
cannot completely rule out the possibility that they may bind
at distinct chromosomal locations. We propose that stimula-
tion of keratinocyte differentiation results in an increase in
AP1 factor (JunB, JunD, and Fra-1) levels and enhanced
binding of AP1 to the DRR region. This, in turn, leads to
increased recruitment of p300 and P/CAF to this region, and
subsequent deacetylation of histones and other transcrip-
tional factors ultimately leads to increased hINV gene
transcription.
MATERIALS AND METHODS
Antibodies and reagents
Rabbit polyclonal antibodies specific for the transcription factors
Fra-1 (sc-605X), JunB (SC-46X), JunD (sc-74X), c-Jun (sc-1694X), and
Sp1 (sc-59X) were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA), and diluted 1:500 for immunoblot. Rabbit polyclonal
antibodies specific for P/CAF (Ab12188) was purchased from Abcam
Inc., (Cambridge, MA) and used for immunoblot at a dilution of
1:800. The anti-p300 mouse mAb (05–257) was purchased from
Upstate Cell Signaling (Lake Placid, NY), and used for immunoblot at
2mg/ml. Mouse monoclonal anti-FLAG M2 (F3165) and anti-FLAG
M2-agarose (A2220) were obtained from Sigma (Milwaukee, WI).
Mouse monoclonal anti-human b-actin (Sigma, clone AC-15) was
diluted 1:8,000 for immunoblot. Horseradish peroxidase-conjugated
donkey anti-rabbit IgG (NA934) was from Amersham Biosciences
(Piscataway, NJ) and used for immunoblot at a dilution of 1:14,000.
Phorbol ester (TPA) was purchased from Sigma.
Plasmid construction
HA-p300 and HA-p300 (del 33, a dominant-negative form of p300)
were generously provided by Dr Livingston (Eckner et al., 1994). The
P/CAF expression plasmid was kindly provided by Dr Nakatani
(Vassilev et al., 1998). Plasmids for mammalian one- and two-hybrid
assays, pFR-Luc and pCMV-BD, were purchased from Stratagene
(La Jolla, CA). pFR-Luc encodes the GAL4 promoter located upstream
of the luciferase gene, and pCMV-BD encodes the GAL4BD
expressed by the cytomegalovirus (CMV) promoter. To construct
pCMV-BD-FLAG-hFra-1-AD, the complete AD, (amino acids D131-
L271) from hFra-1 (GenBank no. BC016648) was amplified by PCR
using hFra-1 cDNA as template to produce FLAG-hFra-1-AD in which
a FLAG epitope is inserted in-phase upstream of the hFra-1 AD
sequence. This product was inserted into pCMV-BD as an EcoRI/NotI
fragment. Similar methods were used to produce pCMV-BD-FLAG-
hFra-1-AD131–231 and pCMV-BD-FLAG-hFra-1-AD131–188. pCMV-BD-
FLAG-hFra-1-AD (T227E) and pCMV-BD-FLAG-hFra-1-AD (T227A)
were produced by point mutagenesis of pCMV-BD-FLAG-hFra-1-AD
using the Quick Change Mutagenesis system (Stratagene). Additional
plasmids, pCMV-BD-FLAG-hFra-11–271, pCMV-BD-FLAG-hFra-11–231,
pCMV-BD-FLAG-hFra-11–188, which encode truncated forms of full-
length FLAG-hFra-1 were produced using similar methods.
To construct the human involucrin promoter distal regulatory
region luciferase reporter plasmids, pINV-41, which encodes the
hINV basal promoter (Welter et al., 1995), was restricted with KpnI/
PstI and HindIII and NsiI sites was inserted as part of a KpnI/PstI linker.
PCR-generated segments of the hINV DRR were subcloned into this
cassette as HindIII/NsiI inserts to yield pINV-DRR(2,473/1,953),
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pINV-DRR(2,473/1,993), pINV-DRR(2,473/2,043), pINV-
DRR(2,473/2,097) and pINV-DRR(2,473/1,953) AP1-5mm.
Transfection
Human foreskin keratinocytes were isolated and maintained as
previously described (Welter et al., 1995). All experiments used
keratinocytes at the third or fourth passage. For transfection, 1 105
keratinocytes were plated in 2ml of keratinocyte serum-free medium
per 10 cm2 dish. At 24 hours, the cells were transfected with 2 mg of
expression plasmid using 6 ml of Fugene 6 reagent (Roche,
Indianapolis, IN). At 24 hours post-transfection, the medium was
replaced with 2ml fresh medium or medium containing 0.3mM
calcium or 50 ng TPA/ml. Luciferase activity was monitored at
24–72hours post-transfection, and the results were expressed as
luciferase activity/mg protein. Human keratinocytes were obtained
with approval of the human studies review panel and all procedures
follow the Declaration of Helsinki Principles.
Retrovirus production and construction of FLAG-hFra-1 HeLa Z
cells
pLNCX2-FLAG-hFra1 was constructed be inserting the human Fra-1
coding sequence, kindly provided by Dr D Chalbos (Philips et al.,
1998), into pLNCX2 retrovirus (BD Biosciences, San Jose, CA). The
hFra-1 cDNA was amplified as an XhoI/ClaI fragment and cloned
into pGEMT (Promega, Madison, WI). The upstream primer encoded
the XhoI site and a FLAG epitope, and the downstream primer
encoded a ClaI site. The PCR-generated product was then cloned
into pGEMT (Promega) to yield pGEMT-FLAG-hFra-1. The FLAG-
Fra-1 fragment was released with XhoI/ClaI and inserted into XhoI/
ClaI-restricted pLNCX2 to generate pLNCX2-FLAG-hFra-1. The
structure of was confirmed by DNA sequence analysis. Ampho-
Pack-293 retrovirus packaging cells (BD Bioscience) were cultured
in DMEM supplemented with 10% fetal calf serum, 4mM L-
glutamine, 1mM sodium pyruvate, 100U/ml penicillin, and
100mg/ml streptomycin. To produce virus, AmphoPack 293 cells
(1 106 cells/50 cm2 dish) were transfected with 10mg of pLNCX2 or
pLNCX2-FLAG-hFra1 vector and the cells were maintained in 5ml
of medium (DMEM containing 10% fetal bovine serum and L-
glutamine). The culture medium was aspirated at 10 hours post-
transfection, replaced with 10ml of fresh medium, and the cells
were incubated for 48 hours at 371C. The resulting virus-containing
medium was used for infection of HeLa-Z cells.
For this purpose, 1ml of this medium was mixed with 1ml of
fresh medium (DMEM containing 10% fetal bovine serum),
polybrene was added to a final concentration of 5mg/ml, and the
mixture was added to 60% confluent HeLa-Z cells and incubated for
2.5 hours at 371C with occasional mixing. An additional 8ml of
medium was subsequently added, and the cells were incubated for
an additional 2 days. The cells were then selected with 0.5mg/ml
G418 (Gibco, Pittsburgh, PA) and candidate clones were isolated
using cloning rings and positively identified as FLAG-hFra-1
producers by immunoblot using mouse monoclonal M2 anti-FLAG
(Sigma, 01865). These clones were then expanded.
Bulk culture of FLAG-hFra-1 HeLa-Z cells and preparation of
HeLa-Z nuclear extracts
Approximately 2 106 FLAG-Fra-1 expressing HeLa-Z cells, were
grown attached in a 50 cm2 dish in 30ml of growth medium (DMEM
containing 10% fetal bovine serum and L-glutamine). The
cells were harvested and transferred to suspension culture in
250ml of Joklik media (Sigma, M0518) that was supplemented with
10% fetal bovine serum (Sigma, F- 6178) and 0.5mg/ml G418
(Gibco, 10131-035). The culture was maintained at 371C with
stirring for 5 days. The suspension was then transferred to 3 l of
G418-free medium and growth, with stirring, was continued at 371C
for an additional 14 days. The cells were then collected by
centrifugation at 1,000 g, washed twice with 0.2mM phenyl-
methylsulfonyl fluoride-containing phosphate-buffered saline, and
resuspended in 30ml of ice-cold hypotonic buffer (10mM Tris-HCl,
pH 7.3, 10mM KCl, 1.5mM MgCl2). All subsequent steps were
performed at 41C.
Nuclear extracts were prepared using the procedure of Dignam
(Dignam et al., 1983) and 2.5mg of nuclear extract, in 5ml, was
loaded onto a 6ml P11 phosphocellulose column (Whatman, Kent,
OH) at a flow rate of 1ml/min. The column was then equilibrated
with 2 column volumes of equilibration buffer (20mM Tris-HCl, pH
7.9, 0.2mM EDTA, 0.5mM phenylmethylsulfonyl fluoride, 1mM
DTT, and 0.1 M KCl and 20% glycerol), and bound proteins were
eluted by increasing the concentration of KCl in 0.1 M increments
(Kershnar et al., 1998). The fractions were collected and stored
frozen at 801C.
Immunological analysis
Equal amounts of protein were separated by electrophoresis on 5 or
10% denaturing polyacrylamide gels, and transferred to PROTRAN
BA83 nitrocellulose membrane (Schleicher and Schuell, Keene,
NH). The membranes were blocked in 10mM Tris-HCl, pH 7.2,
containing 100mM NaCl, 0.1% Tween-20, and 5% nonfat dry milk,
and then incubated overnight at 41C with primary antibody. The blot
was washed and then exposed to an appropriate horseradish
peroxidase-conjugated secondary antibody, and bands were visua-
lized using a chemiluminescent detection system (Amersham
Biosciences).
ChIP analysis
Human keratinocytes were grown to a final concentration of 3 106
cells per 150mm plate and chemically crosslinked with formalde-
hyde (Fisher Scientific, Grand Island, NY) at a final concentration of
1%. After 15minutes at 251C, fixation was stopped by the addition of
glycine to a final concentration of 0.125M. The cells were rinsed
twice with cold phosphate-buffered saline, harvested, and incubated
on ice for 15minutes in 0.3ml of cell lysis buffer containing 5mM
Pipes-KOH, pH 8, 85mM KCl, 0.5% NP-40, 0.5mM phenylmethyl-
sulfonyl fluoride, and 1mg/ml leupeptin and 1mg/ml aprotinin
(Solomon and Varshavsky, 1985). The nuclei were collected at
6,000 g and resuspended in 200 ml of sonication buffer containing
50mM Tris-HCl, pH 8, 10mM EDTA, and 1% SDS. Following
incubation on ice for 10min, the nuclei were sonicated six times for
10 seconds each on setting four with a Sonic Dismembrator-60
(Fisher Scientific) and centrifuged at 15,000 g for 10minutes at
41C. The chromatin-containing supernatant was diluted five-fold
with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2mM
EDTA, 16.7mM Tris-HCl, pH 8.1, 167mM NaCl) and then precleared
by addition of 60 ml of salmon sperm DNA/Protein A beads (Upstate
Cell Signaling) for 30minutes at 41C, followed by centrifugation at
15,000 g for 5minutes.
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Before immunoprecipitation, an aliquot of extract was set aside
representing 1% of the material used for immunoprecipitation. For
immunoprecipitation, the cleared supernatant was incubated over-
night at 41C with 5mg of either anti-Fra1 (Santa Cruz, sc-605X) or
anti-p300 (Upstate Cell Signaling, 05–257). The immune complex
was collected by binding to 60ml of salmon sperm DNA/protein A
beads for 1 hour at 41C with rotation. Washing and elution of
immune complex were carried out as previously described (Gilmour
et al., 1991). Briefly, the beads were collected by centrifugation at
3,000 g for 5minutes and washed sequentially with low-salt buffer
(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1,
150mM NaCl), high-salt buffer (0.1% SDS, 1% Triton X-100, 2mM
EDTA, 20mM Tris-HCl, pH 8.1, 500mM NaCl), LiCl immune
complex wash buffer (0.25M LiCl, 1% NP-40, 1% deoxycholate,
1mM EDTA, 10mM Tris-HCl, pH 8.1, and finally in TE (10mM Tris-
HCl, pH 8, 1mM EDTA). Crosslinks were reversed by addition of
250ml of elution buffer (1% SDS, 0.1M NaHCO3) and incubation for
15minutes with rotation at 251C, followed by heating at 651C for
4 hours. The released DNA was then precipitated by addition of 2.5
volumes of ethanol and incubation at 201C overnight. The hINV
gene promoter sequence was detected by PCR using the promoter-
specific upstream (50-TCAGCCCTAGAATGTTGAGG) and down-
stream (50-TCATGACCTCTCTGTTCC) primers to amplify nucleo-
tides 2,282/1,813 of the hINV promoter. The 470-bp PCR
product was separated by electrophoresis on a 1% agarose gel and
detected using ethidium bromide.
Co-immunoprecipitation analysis
Nuclear extract (5mg/ml) was diluted 1:1 with Tris-buffered saline
(50mM Tris-HCl, 150mM NaCl, pH 7.4) containing 0.2mM
phenylmethylsulfonyl fluoride and 1 mg/ml each of aprotinin,
leupeptin, and pepstatin, and incubated with 40 ml of a 50% slurry
of anti-FLAG M2-agarose (Sigma) for 2 hours at 41C with gentle
rotation. Immune complexes were then collected by centrifugation
at 1,000 g for 2minutes and washed three times with modified
radioimmunoprecipitation assay buffer (20mM Tris-HCl, pH 7.4,
150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100). The
immune complexes were eluted from the M2-agarose with Laemmli
sample buffer, and separated by denaturing and reducing
PAGE. Proteins were transferred onto Protran BA 83 membrane
(Whatman) and incubated with the appropriate primary and
secondary antibodies, and antibody binding was visualized using
chemiluminescence detection reagents (Amersham Pharmacia,
Piscataway, NJ).
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